Promising combo for Hard-to-Treat cancers hits early snag

NCT ID NCT05082025

Terminated Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of two drugs, copanlisib and fulvestrant, in people with advanced hormone receptor-positive (ER+ and/or PR+) cancers of the ovary, endometrium, or breast that also have certain genetic changes (PI3K/PTEN). Only 7 people took part before the study was stopped early. The goal was to see if the combination was safe and effective, but the small size and early termination mean we cannot draw firm conclusions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Copanlisib (a PI3K inhibitor) and fulvestrant (a hormone therapy)
What this could lead to: If successful, this combination could offer a new treatment option for certain advanced hormone receptor-positive cancers that have specific genetic changes.
What could go wrong: This was a very small, early-phase trial that was terminated early, so results are limited and may not apply to larger populations. The combination may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer endometrial cancer endometrium neoplasm ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL CANCER OVARIAN CANCER

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.